| Nr. | Year OPEN | Title | users say | rate good | rate bad | no link | Citation |
|---|
ElectrocardiographyQT timeHeart (Torsade de pointes)Drug developmentLong QT syndrome| 1 | 2000 | QT dispersion in medicine: electrophysiological holy grail or fool's gold? | 
| + | - | nl | QJM 93(7):425-31 (2000) |
| 2 | 1999 | The clinical value of QT dispersion: new perspectives on the assessment of cardiac repolarization more than 75 years after Bazett's formula. |
| + | - | nl | Europace 1(2):73-6 (1999) |
| 3 | 2007 | Short QT: when does it matter? |
| + | - | nl | Circulation 116(7):686-8 (2007) Viswanathan MN |
| 4 | 2000 | Measurement, interpretation and clinical potential of QT dispersion. |
| + | - | nl | J Am Coll Cardiol 36(6):1749-66 (2000) |
| 5 | 2007 | Drug-induced QT prolongation and proarrhythmia: an inevitable link? |
| + | - | nl | Europace 9 Suppl 4(-):iv16-22 (2007) |
| 6 | 2007 | Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias. |
| + | - | nl | Europace 9 Suppl 4(-):iv37-44 (2007) |
| 7 | 2007 | Ionic, molecular, and cellular bases of QT-interval prolongation and torsade de pointes. |
| + | - | nl | Europace 9 Suppl 4(-):iv4-15 (2007) |
| 8 | 2010 | Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives. |
| + | - | nl | Br J Pharmacol 159(1):58-69 (2010) Shah RR |
| 9 | 2010 | Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development. |
| + | - | nl | Br J Pharmacol 159(1):34-48 (2010) Salvi V |
| 10 | 2003 | What clinicians should know about the QT interval. |
| + | - | nl | JAMA 289(16):2120-7 (2003) |
| 11 | 2003 | Congenital and acquired long QT syndromes. | 
| + | - | nl | Can J Cardiol 19(1):76-87 (2003) |
